Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series.

This publication reports on five patients with advanced cancers—ranging from microsatellite stable rectal and colon adenocarcinomas to high-grade neuroendocrine and deficient mismatch repair prostate carcinomas—who experienced prolonged progression-free survival (34 to 69+ months) following anti-CTLA4/anti-PD1 immunotherapy after failing standard treatments.

Key points include:

• Four patients experienced grade 3 immune-related adverse events that were successfully managed, allowing continuation of therapy.
• PET/CT imaging showed complete responses in three of four patients who initially had partial responses.
• These cases highlight the potential for exceptional durable outcomes in selected advanced cancer patients using immunotherapy.
• The findings emphasize the importance of personalized monitoring for immune-related toxicities.
• Ongoing efforts are needed to identify predictive biomarkers for treatment response and toxicity.